Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3335)	10/3/2002 9:29:34 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 10345

no meat here, just posting as tickler for those who have access to the journal...... Nat Rev Neurosci 2002 Oct;3(10):824-8 Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Schenk D. Dale Schenk is at Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, California 94080, USA. dale.schenk@elan.com The agents that are available at present for the management of Alzheimer's disease treat only the symptoms of neurodegeneration and, at best, result in modest, short-term improvements in cognitive function. Immunotherapy represents one of the first tests of the amyloid hypothesis in the clinic, and is an evolving approach to the treatment of Alzheimer's disease that offers a genuine opportunity to modify disease progression. Although initial clinical trials of one approach met with some setbacks, active or passive immunization holds great potential for treating or even preventing Alzheimer's disease.